Australia's TGA Approves Updated Indication for TRUQAP (capivasertib)

The Therapeutic Goods Administration (TGA) in Australia has approved an updated indication for TRUQAP (capivasertib). This approval follows the evaluation of additional clinical data. Healthcare professionals are advised to consult the updated Product Information for comprehensive prescribing details and guidance on biomarker testing.